Szewczuk | Biomedical and Molecular Sciences | School of Medicine

Myron R. Szewczuk PhD

Position(s)

Professor

Contact Info

szewczuk@queensu.ca

Botterell Hall, Room 828

613-770-6403

Please Note: I unfortunately do not have space to accept any new graduate students at this time.

Faculty Bio

B.Sc. (Hons.) 1971 - University of Guelph; Physical chemistry
MSc 1972 - University of Guelph; Biochemistry and thermodynmics of protein-protein interactions. Supervisor - Dr. Rattray
PhD 1974- University of Windsor; Biology and immunochemistry. Supervisor - Dr. T.K. Mukkur
Killiam Post-doctoral Research Scholar - Cornell University Medical College, New York City, U.S.A. Cellular immunology, with Dr. Greg Siskind (01/1975 - 05/1977).
NIH Post-doctoral Research Scholar - Cornell University Medical College, New York City, U.S.A. Cellular immunology, with Dr. Greg Siskind (05/1977 - 06/1978).
Research Associate - Cornell University Medical College, New York City, U.S.A. Aging of the immune system, with Drs. Greg Siskind and Marc Weksler (09/1975 - 06/1978).
Assistant Professor - Department of Pathology and Host Resistance, McMaster University, Hamilton, Ontario (07/1978 - 06/1981)
Associate Professor - Department of Microbiology & Immunology, Queen's University, Kingston, Ontario (07/1981 - 06/1987)
Associate Professor - Department of Medicine, Queen's University, Kingston, Ontario (08/1988 - present)
Full Professor - Department of Micriobiology& Immunology, Queen's University, Kingston, Ontario (07/1987 - 06/2011)
Full Professor - Department of Biomedical & Molecular Sciences, Queen's University, Kingston, Ontario (07/2011 - present)
Appointed Honorable Editor-in-Chief - MOJ Polymer Science (01/30/2018)

Special Issue “100th Anniversary of Insulin: Insulin Receptor Signaling in Health and Disease.”

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section “Cellular Biochemistry.” Deadline for manuscript submissions: 15 February 2022.

Special Issue Editors

Dr. Myron R. Szewczuk E-Mail Website SciProfiles

Guest Editor

Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada
Interests: cancer; inflammation; insulin receptor signaling; glycosylation; NEU1 sialidase

Dr. Fiona Haxho E-Mail Website SciProfiles

Guest Editor

Faculty of Medicine, University of Toronto, Toronto, ON, Canada
Interests: medicine; inflammation; insulin receptor signaling; glycosylation; Neu1 sialidase

Dr. Fiona Haxho, M.D., Ph.D. was my former Ph.D. student and Vanier Canada Graduate Scholar in the department. She is presently doing her Residency program in Dermatology at the University of Calgary.

Special Issue Editors

Myron R. Szewczuk, PhD Email | Website
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada
Interests: immunology; cancer; COVID-19; glycosylation; cannabis; nanomedicine; receptor signaling

Editorial Board Member

Discovery Medicine
Impact Factor: 3.222
Indexing: Web of Science (WOS), PubMed (MEDLINE)
Print ISSN: 1539-6509
Electronic ISSN: 1944-7930

Myron R. Szewczuk Website, SciProfiles
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada
Interests: immunology; COVID-19 and ACE2 receptor; cancer; inflammation; TLR receptor; Trk receptor; GPCR signaling; insulin receptor; glycosylation; NEU1 sialidase
Special Issues, Collections and Topics in MDPI journals

Section Board Member

Biomolecules https://www.mdpi.com/journal/biomolecules
Impact Factor: 6.064 (2021); 5-Year Impact Factor: 6.191 (2021)
Indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (Biochemistry & Molecular Biology) / CiteScore - Q2 (Biochemistry)

International Conference on Cancer Research & Nucleic Acids 2021

Theme: Next Generation Multimodality of Nanomedicine Therapy: From smart targets, models, and gene alterations

March 11 - 12, 2021, 09.00 - 15.30 EST/ 14.00 – 20.30 GMT. CME Accredited “Virtual Conference”

Dr. Szewczuk, Dr. Jean-Yves Masson (Jym) (Université Laval) and Dr. Samer Hussein (Université Laval) are the conference co-organizers and Scientific Chairs.
https://theresearchgate.com/conferences/international-conference-on-cancer-research-nucleic-acids-2021/

International Conference on Cancer Science and Therapeutics

Dr. Szewczuk is the Conference Chair and Scientific Officer

Theme: Global Advances in Oncology & Cancer Research

DoubleTree by Hilton Hotel Orlando, August 13th-15th, 2020

CME Accredited

https://theresearchgate.com/conferences/cancer-science-therapeutics-2020/

Research interests:

Alternate therapeutic treatment of cancer.
The role of glycosylation in the activation of neurotrophin Trk, EGFR, insulin and TOLL-like receptors.
Molecular basis of Neu1 sialidase underlying TOLL-like receptor activation in pathophysiology of infections and inflammation.
N-Acylated Hexosamines as Nutraceuticals: From Shellfish to Algae to Mammalian Bone and Joint Health.
Trypanosome trans-sialidase for neuronal differentiation and neuroprotection from apoptosis
Biased G protein-coupled receptors agonism
Insulin receptor in diseases
Medicinal Marijuana
Alternate therapeutic approach in the treatment of human cancer
The role of glycosylation in receptor activation
Molecular basis of Neu1 sialidase underlying TOLL-like receptor activation in pathophysiology of infections and inflammation
N-Acylated Hexosamines as Nutraceuticals: From Shellfish to Algae to Mammalian Bone and Joint Health
Trypanosome trans-sialidase for neuronal differentiation and neuroprotection from apoptosis

Details of Research Interests:

(A) Cancer Research:
The cancer research initiated and funded by a private-sector donor was focused to evaluate an alternate therapeutic approach in the treatment of human pancreatic cancer. This approach is based on our reports identifying the key players involved in ligand-binding and receptor activation to a novel receptor-signaling platform and its targeted translation in human disease. The cancer research identified for the first time that Neu1 sialidase may be an important cancer-targeting enzyme which acts at the receptor level signaling platform on the cell surface to modulate a number of glycosylated receptors such as epidermal growth factor, nerve growth factor TrkA, insulin and TOLL-like receptors, all of which are known to play major roles in cancer. We have identified an alternate treatment strategy being in the form of a horizontal approach, of which several important cancer growth factor receptor signaling platforms, oncogenic pathways, cancer cell survival in acquired chemo-resistance and macrophage-mediated tumor progression are targeted with promising therapeutic intent. International PCT/CA2011/050690 patent filing November 04, 2011

(B) Inflammation
The mammalian Toll-like receptors (TLRs) are one of the families of sensor receptors that recognize pathogen-associated molecular patterns (PAMPs). Not only are TLRs crucial sensors of microbial (e.g., viruses, bacteria and parasite) infections for innate immune cells, they also play an important role in the pathophysiology of infectious, inflammatory and autoimmune diseases. Thus, the intensity and duration of TLR responses against infections and inflammatory diseases must be tightly controlled. Although the signaling pathways of TLR sensors are well characterized, the parameters controlling interactions between the sensors and their ligands still remain poorly defined. We have recently identified a novel mechanism of TLR activation by its natural ligand, which has not been previously observed (Amith et.al. 2009 Glycoconj J). It suggests that ligand-induced TLR activation is tightly controlled by Neu1 sialidase activation. Our data indicate that Neu1 sialidase is already in complex with TLR-2, -3 and -4 receptors, and is induced upon ligand binding to either receptor. Activated Neu1 sialidase then hydrolyzes sialyl a-2,3-linked β-galactosyl residues distant from ligand binding to remove steric hinderance to TLR-4 dimerization, MyD88/TLR4 complex recruitment (Amith et.al. 2009 Cell Signaling), NFkB activation and pro-inflammatory cell responses (Amith et.al. 2009 Glycoconj J). We know that neuraminidase inhibitor Tamiflu (oseltamivir phosphate) blocks TLR ligand induced NFkB activation, nitric oxide (NO) production and pro-inflammatory cytokines (Amith et.al. 2009 Glycoconj J). We have reported to date that TLR ligand binding induces a receptor conformational change to mediate GPCR-signaling via membrane Gαi-proteins and matrix metalloproteinase-9 (MMP-9) to activate Neu1. In addition, we have identified the key players involved in the activation of nucleic acid sensing intracellular TLR-7 and -9 receptors against imiquimod and CpG oligodeoxynucleotide (ODN), respectively. It discloses a striking identical signaling paradigm as described for the cell-surface TLRs and for receptor tyrosine kinases such as Trks, epidermal growth factor and insulin. Here, Neu1 sialidase and matrix metalloproteinase-9 (MMP9) cross-talk in alliance with G-protein coupled receptor (GPCR) neuromedin-B tethered to TLR-7 and -9 receptors at the ectodomain forms a novel molecular organizational GPCR signaling platform that is essential for ligand activation of the TLRs and cellular signaling. These findings radically redefine the current dogma(s) governing the essential activating molecules tethered to nucleic acid sensing TLRs as well as to cell surface sensing TLRs, which may provide pioneering molecular targeting approaches to disease intervention strategies.

(C) Insulin receptor signaling
We have uncovered a novel Neu1 and matrix metalloproteinase-9 (MMP-9) cross-talk in alliance with neuromedin B G-protein coupled receptor (GPCR), which is essential for insulin-induced IR activation and cellular signaling. Neu1, MMP-9 and neuromedin B GPCR form a complex with IRβ subunit on the cell surface. Our findings identify a novel insulin receptor-signaling platform that is critically essential for insulin-induced IRβ tyrosine kinase activation and cellular signaling.

Lab

Teaching Philosophy

provide safe space to grow
open career doors
defend us when we needed it
recognize and reward us
develop us as leaders
inspire us to stretch higher
lead by example
tell us our work matters
forgive us when mistakes were made
teach us how to think, not what to think
Continue to remain a friend, mentor and guide.

Mitacs Accelerate Postdoctoral Fellowship

Dr. Reza Bayat Mokhtari, Ph.D., is the recipient of the Mitacs Accelerate Postdoctoral Fellowship on the research project entitled, “Mechanism of CoVID-19 induced hyper inflammation” in the Department of Biomedical and Molecular Sciences under the Internship Supervisor of Dr. Myron Szewczuk and Dr. William Harless, M.D., Ph.D. and CEO of the Partner Organization, Encyt Biotechnologies, Inc., Nova Scotia, Canada. Dr. Mokhtari received his Ph.D. from the Institute of Medical Science, University of Toronto, Toronto, Ontario, under the supervision of Dr. Herman Yeger.

Publications

Reza Bayat Mokhtari 1,2, Neda Ashayeri 3‡, Leili Baghaie 2‡, Manpreet Sambi 2‡, Kosar Satari3, Narges Baluch 4, Dmitriy A. Bosykh 1, Myron R Szewczuk 2, and Sayan Chakraborty 1*. The Hippo pathway effectors YAP/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment. Cancers 2023, 15(13)3468, https://doi.org/10.3390/cancers15133468; Special Issue New Insights on the Hippo-YAP/TAZ-TEAD Pathway and Its Roles in Cancer (Impact factor: 6.886 (2021), CiteScore- Q! (Oncology), indexed PubMed).
Bessi Qorri 1, Reza Bayat Mokhtari 1, William W. Harless 2,* and Myron R. Szewczuk 1,*. Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases. Cancers 2022, 14, 3595, https://doi.org/10.3390/cancers14153595 (5-Year Impact Factor: 6.886 (2021), indexed PubMed).
Bessi Qorri1, Reza Bayat Mokhtari1, William W. Harless2,* and Myron R. Szewczuk1,* Drug repurposing in cancer therapy: aspirin and oseltamivir phosphate in combination with gemcitabine actively target the PI3K/Akt/mTOR survival pathways and disable hypoxia and the epithelial-to-mesenchymal transition to reduce cancer stem cells in pancreatic cancer. Cancers 2022, 14, x. (Impact factor 6.639, 2022, indexed PubMed).
Bessi Qorri1, Reza Bayat Mokhtari1, William W. Harless2,*, and Myron R. Szewczuk1,*. Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression. Cancers 2022, 14(6), 1374; https://doi.org/10.3390/cancers14061374. (Impact factor 6.639, 2022, indexed PubMed).
Reza Bayat Mokhtari 1,2,*,†, Manpreet Sambi 1,†, Bessi Qorri 1, Narges Baluch 3, Neda Ashayeri 4, Sushil Kumar 5, Hai-Ling Margaret Cheng 6,7, Herman Yeger 8, Bikul Das 2,9 and Myron R. Szewczuk 1,*. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers 2021, 13, 3596. https://doi.org/10.3390/cancers13143596
Reza Bayat Mokhtari1,2,9,*, Bessi Qorri2, Narges Baluch3, Angelo Sparaneo4, Federico Pio Fabrizio4, Lucia Anna Muscarella4, Albina Tyker5, Sushil Kumar6, Hai-Ling Margaret Cheng7, Myron R Szewczuk2,*, Bikul Das8,9,10 and Herman Yeger1,* Next-Generation Multimodality of Nutrigenomic Cancer Therapy: Sulforaphane in Combination with Acetazolamide Actively Target Bronchial Carcinoid Cancer in Disabling PI3K/Akt/mTOR Survival Pathway and Inducing Apoptosis. Oncotarget 2021; 12:1470-1489. https://doi.org/10.18632/oncotarget.28011 (Impact Factor 5.126, indexed PubMed).
Reza Bayat Mokhtari1,2,‡, Bessi Qorri1, Manpreet Sambi1, Narges Baluch3, Sushil Kumar4, Bikul Das2,5, Myron Szewczuk1,‡, Herman Yeger6,‡, Hai-Ling Margaret Cheng7,‡ 3D Multicellular Stem-like Human Breast Tumor Spheroids Enhance Tumorigenicity of Orthotopic Xenografts in Athymic Nude Rat Model. 2021 Cancers 13(11), 2784 (Impact Factor 6.126, indexed PubMed) https://doi.org/10.3390/cancers13112784

2023 Mitacs Globalink Research Internship (GRI)

Fleur Leroy was the recipient of the 2023 Mitacs Globalink Research Internship (GRI) (July-September 2023) on the research project entitled "Tumor Angiogenesis Toward Progression and Metastatic Potential" in the Department of Biomedical and Molecular Sciences under the Internship Supervisor of Dr. Myron Szewczuk. Mademoiselle Fleur Leroy is a 3rd-year etudiant(e) en medecine, Faculte de Medecine, Maieutique et Sciences de la Sante, Universite de Strasbourg, F-67000 Strasbourg, France.

Publications:

Moshe, D.L.; Baghaie, L.; Leroy, F.; Skapinker, E.; Szewczuk, M.R. Metamorphic Effect of Angiogenic Switch in Tumor Development: Conundrum of Tumor Angiogenesis Toward Progression and Metastatic Potential. Biomedicines 2023, 11, 2142. doi: 10.3390/biomedicines11082142.
Baghaie, L.; Leroy, F.; Sheikhi, M.; Jafarzadeh, A.; Szewczuk, M.R.; Sheikhi, A. Contemporaneous SARS-CoV-2 Neutralizing Antibodies Mediated by N-glycan Shields. Viruses 2023, 15(10), 2079. https://doi.org/10.3390/v15102079 (registering DOI). Received: 19 August 2023 / Revised: 3 October 2023 / Accepted 9 October 2023 / Published: 12 October 2023 (This article belongs to the Special Issue SARS-CoV-2: Vaccine Design and Host Immunity)
Junsu Lee 1, Hyunmin Lee 1, Adham El Sherbini 1, Leili Baghaie 2, Fleur Leroy 2,3, Husam Abdel-Qadir 4, Myron R. Szewczuk 2, and Mohammad El-Diasty 5 *. Epigenetic MicroRNAs As Prognostic Markers of Post-Operative Atrial Fibrillation, A Systematic Review. Current Problems in Cardiology (IF 4.2) Accepted for publications.
Baghaie, L.; Haxho, F.; Leroy, F.; Lewis, B.; Wawer, A.; Minhas, S.; Harless, W.W.; Szewczuk, M.R. Contemporaneous Perioperative Inflammatory and Angiogenic Cytokine Profiles of Surgical Breast, Colorectal, and Prostate Cancer Patients: Clinical Implications. Cells 2023, 12, 2767. https://doi.org/10.3390/cells12232767

Graduate Trainees

Ph.D. students

Fiona Haxho: Queen’s Graduate Award (QGA), the Graduate Entrance Tuition Award (GETA), the Natural Sciences and Engineering Research Council of Canada (NSERC) Alexander Graham Bell Canada Graduate Scholarship-Master’s (CGS M) and the 2016 Vanier Canada Graduate Scholarship. Started M.Sc. 09/14, mini-MSc defence 08/16 into Ph.D., completed Ph.D. Comprehensive exam June 20, 2017, completed Ph.D. dissertation defense July 31, 2017; accepted the MD program at the University of Toronto starting September 2017, and graduated with MD degree in April 2020. Dr. Haxho, MD, Ph.D. is doing her MD Residency program at the University of Calgary, specializing in Dermatology.

Manpreet (Ruby) Sambi: Queen’s Graduate Award (QGA), and 2018 The Office of Postgraduate Medical Education Queen’s University Recognition Award. Started Ph.D. 09/16, completed Ph.D. Comprehensive exam 2019, completed Ph.D. dissertation defense January 9, 2020. Co-Editor of Springer Nature Series Book on cancer published Aug 2019, published two (2) Book Chapters, published eleven (11) review articles, published five (5) research articles, presented four (4) International and National Oral Conference Keynote speeches.

Bessi Qorri: 2017 Terry Fox Research Institute Transdisciplinary Training Program in Cancer Research Scholarship, 2017 Queen’s Graduate Award, 2018 The Office of Postgraduate Medical Education Queen’s University Recognition Award,2018, 2019, 2020 Dean’s Doctoral and 2020-21 the Queen Elizabeth II Graduate Scholarships in Science and Technology (QEII-GSST), and the 2021 R.S. McLaughlin Fellowship, and 2019-20 Vanier Canada Graduate Scholarship (C.G.S.) - Selected by the School of Graduate Studies to the National Competition. M.Sc. degree program started May 1, 2017, completed Mini-Master into Ph.D. program August 2018, Ph.D. degree program began September 1, 2018, completed Ph.D. Comprehensive examination April 2020; completed Ph.D. dissertation defence August 15, 2022. Bessi’s research accomplishments are outlined as follows: Peer-reviewed Research Articles: 7 (4 out of 7 are first authorships), 16 peer-reviewed Review Articles, four peer-reviewed book chapters, peer-reviewed Springer Nature Series Book on cancer co-editor, and eight International/National Invited Keynote Speaker.

M.Sc. students

Leili Baghaie Naeeni: September 2022; Queen’s Graduate Award (QGA), FHS Graduate Fund (FHSGF). Completed MSc in May 2024. Contributing authorships on fourteen (14) peer-reviewed published articles. Presently accepted into MSc degree program in Public Health at the University of Toronto.

David A. Bunsick: September 2022; Queen’s Graduate Award (QGA), FHS Graduate Fund (FHSGF). Completed MSc in June 2024. Contributing authorships on eight (8) peer-reviewed published articles. Presently accepted as a researcher at a Boston Hospital in the U.S.A.

Sabah Haq, M.D. Ph.D.: Queen’s Graduate Award (QGA), and 2016 Ontario Graduate Scholarship (OGS)(started September 2015 -completed M.Sc. June 21, 2017; Ph.D. position at McMaster University, completed Ph.D., 2021; Postdoctoral position at the University of Nebraska.

Bessi Qorri, Ph.D.: May 2017, completed the mini-Master (August 21, 2018), Queen’s Graduate Award (QGA), Encyt Technologies, Inc. and 2017 Terry Fox Research Institute Transdisciplinary Training Program in Cancer Research. Completed Ph.D. August 2022.

Vanessa Samuel: Combined BScH/MSc (declined). Accepted UBC MD program, M.D. offers at Calgary and Queen’s.

Nicka Kalaydina: September 2017, Queen’s Graduate Award (QGA), Encyt Technologies, Inc., and 2018 The Office of Postgraduate Medical Education Queen’s University Recognition Award. (completed M.Sc. August 2019, Research associate with Stem Cell Technologies, Inc. Vancouver, BC, offered M.D, program at the University of Calgary, accepted M.D. program at UBC starting September 2020

Alexandria DeCarlo: B.Sc. (Hons.) Biotechnology, Department of Biology, Queen’s University (2019); M.Sc. degree program started May 2019 in Biomedical and Molecular Sciences, and co-supervised by Dr. Cecile Malardier-Jugroot, Professor and Head of Chemistry and Chemical Engineering and Vice-Principal of Research, Royal Military College, Kingston, Ontario. 2019-20 Queen’s Graduate Award (QGA). Completed M.Sc. July 2020. Contributing authorships on three peer-reviewed published articles, contributing authorship on one (1) book chapter, contributing authorship on two (2) review articles and presented three (3) oral speeches at national & international conferences. She was accepted into the Ph.D. program in the Department of Medical Biophysics Graduate - Medical Biophysics at the University of Toronto to start in September 2020.

Graduate Diploma and Professional Master in Medical Sciences (GDPM)

July 2017	January 2018	July 2018
Andrey Vishnyakov, MD	Iryna Liauchonak, MD	Arifuddin Saad Mohammed, MD
Anmol Lamba, MD	Fady Dawoud, MBBCh	Shamira Pira, MD
Catherine Nowierski, MSc, MD	Yatin Riat, MD	Jabiz Modaresi Esefh, MD, PhD
S.M. Signy Frank, MBBS	Justin Jain, MD
Umrao Bhatti, MBB	Komal Bajwa, MBBS
Yara Mouhamed, MBBCh

GDPM Publications:

Iryna Liauchonak^1,4, Bessi Qorri2,4, Fady Dawoud^1,4,Yatin Riat1,^3,4, and Myron R. Szewczuk^2,* Non-nutritive Sweeteners and their Implications on the Development of Metabolic Syndrome. Nutrients 2019, 11, 644. http://dx.doi.org/10.3390/nu11030644  (impact factor 4.6, indexed PubMed). Received: 28 February 2019; Accepted: 13 March 2019 after extensive peer-review; Published:16 March 2019. ¹Graduate Diploma and Professional Master in Medical Sciences, Postgraduate Medical Education, School of Medicine, Queen’s University, Kingston, ON, Canada; ²Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ³Present address: Emergency Medicine, Resident Physician, Brooklyn Hospital Centre, 121 DeKalb Avenue, Brooklyn, N.Y. 11201, USA. ⁴Contributing first authorship
Justin Jain^1,3, Bessi Qorri^{2, 3} and Myron R. Szewczuk^1,2,*. The Crucial Role of Primary Care Providers in the Long-term follow up of Adult Survivors of Childhood Cancer. 2018 Cancer Management and Research (impact factor 3.702, indexed PubMed). submitted for publication December 09, 2018, under peer-review, accepted for publication February 02, 2019. ²Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ¹Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; ³Contributing first authorship
Regina-Veronicka Kalaydina^1,4, Komal Bajwa^2,4, Bessi Qorri^1,4, Alexandria Decarlo³, and Myron R. Szewczuk^1,* Recent advances in “smart” delivery systems for extended drug release in cancer therapy. International Journal of Nanomedicine 2018:13 4727–4745, extensive peer-reviewed, indexed in PubMed Central (impact factor: 5.008). DOI https://doi.org/10.2147/IJN.S168053. ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; ³Department of Biology, Queen’s University, Kingston, ON, Canada; ⁴Contributing first authorship
Iryna Liauchonak MD^1,3, Fady Dawoud MBBCh^1,3, Yatin Riat MD^1,3, Bessi Qorri BSc^2,3, Manpreet Sambi MSc^2,3, Justin Jain MD¹, Regina-Veronicka Kalaydina BSc², Nicole Mendonza², Komal Bajwa MBBS¹, and Myron R. Szewczuk PhD^2,* Biased G-protein coupled receptor agonism bridges the gap between the insulin receptor and metabolic syndrome. Int. J. Mol. Sci. 2018, 19, 575. (Impact factor: 3.2), indexed in PubMed Central; Received: 1 February 2018 / Revised: 11 February 2018 / Accepted: 15 February 2018 / Published: 17 February 2018. ¹Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; ² Department of Biomedical and Molecular Science, Queen’s University, Kingston ON, Canada; ³ Contributing first authorship. doi:10.3390/ijms19020575
Yara Mouhamed^1,3, Andrey Vishnyakov^1,3, Bessi Qorri^2,3, Manpreet Sambi^2,3, Signy Frank¹, Catherine Nowierski¹, Anmol Lamba¹, Umrao Bhatti¹, and Myron R Szewczuk²^,*. Therapeutic Potential of Medicinal Marijuana: An Educational Primer for Healthcare Professionals. 2018 Drug, Healthcare and Patient Safety 10: 45–66, indexed in PubMed Central; submitted 16/Jan/2018, extensive peer-review, accepted for publication March 9, 2018. ¹Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University. ²Department of Biomedical and Molecular Sciences, Queen’s University. ³Contributing first authorship. https://www.dovepress.com/therapeutic-potential-of-medicinal-marijuana-an-educational-primer-for-peer-reviewed-article-DHPS
Manpreet Sambi^1,3, Bessi Qorri^1,3, S.M. Signy Frank², Yara Mouhamed², Regina-Veronicka Kalaydina¹, Nicole Mendonza¹, and Myron R. Szewczuk^1*. Novel Use of Peptides to Facilitate the Formation of 3D Multicellular Tumor Spheroids. 2017 Curr Top Pept Protein Res 18, 25-34. indexed in PubMed Central; ¹Department of Biomedical and Molecular Sciences, Queen’s University. ²Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University. ³Contributing first authorship. http://www.researchtrends.net/tia/article_pdf.asp?in=0&vn=18&tid=26&aid…

Undergraduate HSCI Advanced Health Sciences Research

Merry Jesso Abraham (2021-23): Bachelor of Health Sciences. Testimonial: Honoured to have the opportunity to work with these amazing mentors (https://www.linkedin.com/in/merlin-abraham-478ba3b5/recent-activity/all/). Technical Specialist – Q.C. Technical Specialist – QC Drytac Apr 2016 - Present · 7 yrs 4 mos. Publications:

Merlin Jesso Abraham, Adham El Sherbini, Mohammad El-Diasty, Sussan Askari and Myron R. Szewczuk. Restoring Epigenetic Reprogramming with Diet and Exercise to Improve Health-related Disorders. Biomolecules 2023, 13, 318. https://doi.org/10.3390/biom13020318. (5-year Impact Factor: 6.191, CiteScore 5.7, indexed in PubMed) after extensive peer review from experts in the field. Academic Editor(s): Shang-Zhong Xu; Thozhukat Sathyapalan. Received: 17 January 2023, Revised: 30 January 2023, Accepted: 03 February 2023. The manuscript’s contents are part of her scholarly work in the HSCI research course. Acknowledgments: All authors acknowledge the educational and scholarly alliance of the Health Sciences, Faculty Development mentorship program, Office of Professional Development & Educational Scholarship, and the Health Sciences, HSCI BHSc Research program.

Jenna Matsukubo (2022-23): Bachelor of Health Sciences. Recipient of the 2019-2022 Dean’s Honors List with Distinction, the 2022 Nixon Academic Leadership Award, the 2019 Principal’s Entrance Scholarship, the 2019-2022 Academic All-Canadian Award and the 2019-2022 Athletic Financial Award. Offered admission at the University of Ottawa Medical School starting Fall 2023. Publications:

David A. Bunsick, Jenna Matsukubo, and Myron R. Szewczuk. Cannabinoids Transmogrify Cancer Metabolic Phenotype via Epigenetic Reprogramming and a Novel CBD Biased G Protein-coupled Receptor Signaling Platform. Cancers 2023, 15(4), 1030; https://doi.org/10.3390/cancers15041030. (impact factor 6.575, CiteScore 5.8, indexed in PubMed) after extensive peer review from experts in the field. Academic Editors: Kenta Masui and Linlin Guo. Received: 7 January 2023, Revised: 20 January 2023, Accepted: 03 February 2023. The manuscript’s contents are part of her scholarly work in the HSCI research course. Acknowledgments: All authors acknowledge the educational and scholarly alliance of the Graduate Program in Experimental Medicine and the Health Sciences, HSCI BHSc Research program.
2. Jenna Matsukubo †, David A. Bunsick † and Myron R. Szewczuk *. Functional Selectivity of Cannabinoid CB1 GPCR Transactivates Glycosylated Receptors in Health and Disease. Cells 2023,12, xxxx; https://doi.org/10.3390/cells, xxxx. Pending Editor decision. Received Date: 9 May 2023, Revised Date: 19 June 2023. (Impact Factor: 6.0 (2022); 5-Year Impact Factor: 6.7 (2022), indexed in PubMed). Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; 18jem9@queensu.ca (J.M.); 17dab5@queensu.ca (D.A.B.). * Correspondence: szewczuk@queensu.ca; Tel: +1-613-770-6403, † These authors contributed equally to this work.

Undergraduate 4th yr research project students

Shanel Mackay (2018-19): Life Sciences Specialization. I actually just finished my first co-op placement at Scotiabank in Corporate Banking. So now I'm back in school for the summer for the second semester of my MBA. But they seemed to really like my work at Scotia and have asked me to go back for a second co-op in the fall which is great! I never anticipated on pursuing a career in finance, but I've really enjoyed myself so far! It's been a great experience. I also wanted to say thank you for all of the time and patience that you took to teach me during the time I spent in your lab. You've taught me a lot of valuable life lessons that I've been able to take with me while I've pivoted from science to finance. It has helped me to stand out in my interviews and I contribute a lot of those lessons to my success in both my co-op and academically. Thank you for being such an amazing mentor to me!

Alexandra DeCarlo (2018-19): Bachelor of Science, Specialization in Biotechnology (Honours)
Publications:

Bessi Qorri^1, Regina-Veronicka Kalaydina^1, Aleksandra Velickovic^1, Yekaterina Kaplya^1, Alexandria Decarlo^2, and Myron R. Szewczuk^1,* Agonist-biased signaling via matrix metalloproteinase-9 promotes extracellular matrix remodeling. Cells 2018, 7, 117; http://dx.doi.org/10.3390/cells7090117 (impact factor 4.829); full-text archived in PubMed Central. ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²Department of Biology, Biosciences Complex, Queen’s University, Kingston, ON, Canada K7L 3N6. ^*corresponding author
Regina-Veronicka Kalaydina^1,4, Komal Bajwa^2,4, Bessi Qorri^1,4, Alexandria Decarlo^3, and Myron R. Szewczuk^1,* Recent advances in “smart” delivery systems for extended drug release in cancer therapy. International Journal of Nanomedicine 2018:13 4727–4745, extensive peer-reviewed, indexed in PubMed Central (impact factor: 5.008). DOI https://doi.org/10.2147/IJN.S168053.  ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; ³Department of Biology, Queen’s University, Kingston, ON, Canada; ⁴Contributing first authorship
Xia Li^1,6 & Manpreet Sambi^2,6, Alexandria DeCarlo^3, Sergey V Burov^4, Roman Akasov^5, Elena Markvicheva^5, Cecile Malardier-Jugroot^1,* and Myron R Szewczuk^2,* Functionalized folic acid-conjugated amphiphilic alternating copolymer actively targets 3D multicellular tumor spheroids and delivers the hydrophobic drug to the inner core. Nanomaterials 2018, 8, 588; doi:10.3390/nano8080588, extensive peer-reviewed, indexed in PubMed Central (Impact Factor: 3.811). ¹Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON, Canada; ²Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ³Department of Biology, Queen’s University, Kingston, ON, Canada; ⁴Synthesis of Peptides and Polymer Microspheres Laboratory, Institute of Macromolecular Compounds, Russian Academy of Sciences, St Petersburg, Russia; ⁵Department of Biomaterials and Biotechnologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; ⁶Contributing first authors, ^*corresponding authors.

Vanessa Samuel (2016-17): Life Sciences Specialization. Recipient of the Queen’s University Principal’s Scholarship and the Board of Governor’s Award.
Publications:

Roman Akasov, Sabah Haq, Fiona Haxho, Vanessa Samuel, Sergey V. Burov, Elena Markvicheva, Ronald J. Neufeld, and Myron R. Szewczuk. Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic RGD peptide induced self-assembly. 2016 Oncotarget 2016, Vol. 7, No.40 66119-661342016. (impact factor 6.4)
Manpreet Sambi, Sabah Haq, Vanessa Samuel, Bessi Qorri, Fiona Haxho, Kelli Hill, William Harless and Myron R. Szewczuk. Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. Breast Cancer - Targets and Therapy 2017:9 1–9.
Sabah Haq, Fiona Haxho, Vanessa Samuel, Roman Akasov, Maria Leko, Sergey V. Burov, Elena Markvicheva and Myron R. Szewczuk.Sialylation facilitates self-assembly of 3D multicellular prostaspheres using cyclo-RGDfK(TPP) peptide. OncoTargets and Therapy 2017:10 2427–2447, accepted March 08, 2017, as it stands in current form. DOI https://doi.org/10.2147/OTT.S133563

Bessi Qorri (2016-17): Life Sciences Specialization
Publications:

Manpreet Sambi, Sabah Haq, Vanessa Samuel, Bessi Qorri, Fiona Haxho, Kelli Hill, William Harless and Myron R. Szewczuk. Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. Breast Cancer - Targets and Therapy 2017:9 1–9.
Fiona Haxho¹ & Manpreet Sambi^1, Bessi Qorri^1, William Harless, Myron R. Szewczuk. Current clinical challenges and emerging multi-modal approaches for the treatment of pancreatic cancer. Clin Oncol. 2017; 2: 1296, submitted March 11, 2017, accepted for publication April 13, 2017 as it stands in current form. ¹contributing first authors.
Manpreet Sambi^1,2 & Fiona Haxho^1,2, Bessi Qorri^1, William Harless^3*, Myron R. Szewczuk^1*. Pancreatic Adenocarcinoma: Current Therapies and Challenges. Adv Res Gastroentero Hepatol 4(4): ARGH.MS.ID.555643 (2017) 001, submitted April 15, 2017, accepted for publication April 18, 2017 as it stands in current form. ²contributing first authors. ³ENCYT Technologies, Inc. Membertou, NS, Canada. DOI: 10.19080/ARGH.2017.04.555643
Manpreet Sambi¹ & Bessi Qorri¹ and Myron R Szewczuk. Therapeutic options for Metastatic Breast Cancer. Springer Book ‘Breast Cancer Metastasis and Drug Resistance’ – 2nd Volume, in preparation for July 2017 due date. ¹contributing first authors.

All of my graduate students finish “on time, MSc 1.5 yrs and PhD 3yrs” with several publications in high impact (IF≥ 4.3) journals as first and contributing co-authors.

My undergrad 4th yr research project students and NSERC USRA funded students (~ 50%) have contributed as co-authors to our publications.

A high proportion of my trainees have continued in academic or medical careers. Most gratifying and compelling success of my past PhD trainees are now academic faculty members as full professors and/or departmental heads or senior staff scientists in biotech companies.

My recent graduated PhD trainees have MD or post-doctoral positions: Dr. Fiona Haxho, MD, Ph.D. - MD program at the University of Toronto, and now residency in Dermatology at the University of Calgary; Dr. Ray Amith, Ph.D.- Post-doctoral training at the University of Alberta; former Assistant Professor at Keele University, U.K. and now 2022 tenured Assistant Professor in Department of Immunology, University of Toronto; Dr. Preethi Jayanth, Ph.D.-Post-doctoral trainee at McMaster University and Research Scientist at the University of Guelph; Dr. Samar Abdulkhalek, Ph.D.-Post-doctoral training at Cleveland Clinic 1yr; Assistant Professor in UAE

Lab members Bessi Qorri and Manpreet Sambi with Nobel Laureate Andrew Schally

The Nobel Prize in Physiology or Medicine 1977, Roger Guillemin, Andrew V. Schally, Rosalyn Yalow

Prize motivation: "for their discoveries concerning the peptide hormone production of the brain"

Aspects of Hypothalamic Regulation of the Pituitary Gland with Major Emphasis on Its Implications for the Control of Reproductive Processes

2024 Grad Chat with Rashelle Aldbai

Rashelle chats with her academic experiences in the Health Sciences program and now her M.Sc. research program.

Grad Chat--Rashelle Aldbai

Books

Bessi Qorri, Manpreet Sambi, and Myron R Szewczuk (Editors). (2019) Current Applications for Overcoming Resistance to Targeted Therapies. Springer Nature Series (20): 250 pages. Publisher Springer Publisher Nature Series, New York, NY

Springer Nature Series eBook

Book Chapters

Manpreet Sambi, Myron Szewczuk. (2019) Chapter 1: Introduction to the Acquisition of Resistance to Targeted Therapy. Editors M.R. Szewczuk, B. Qorri, M. Sambi. Current Applications for Overcoming Resistance to Targeted Therapies (20): 1-25. Publisher Springer Publisher Nature Series, New York, NY.
Bessi Qorri, Myron R Szewczuk. (2019) Chapter 2: Targeting the Tumor Microenvironment to Overcome Resistance to Targeted Therapy. Editors M.R. Szewczuk, B. Qorri, M. Sambi. Current Applications for Overcoming Resistance to Targeted Therapies. (20): 25-65. Publisher Springer Publisher Nature Series, New York, NY.
Manpreet Sambi, Bessi Qorri, William Harless and Myron R Szewczuk. (2019). Therapeutic options for Metastatic Breast Cancer. Editor Aamir Ahmad, Ph.D. Breast Cancer Metastasis and Drug Resistance. (2): 1-20. Publisher Springer Nature Series Book.
Bessi Qorri¹, Alexandria DeCarlo¹, Cecile.Malardier-Jugroot² and Myron R Szewczuk¹. (2019) Chapter 21: Drug delivery systems for cancer therapy. Editor Dr. Eric Chappel Debiotech SA, Microsystems Department, Lausanne 1004, Switzerland. Series Editor Dr. Dennis Fitzpatrick School of Computing and Engineering, University. Drug Delivery Devices and Therapeutic Systems 1-19. Publisher Elsevier. ¹Dept. Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario K7L 3N6; ²Dept. of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON K7K 7B4.
Abdulkhalek, S., Amith, S.R. and Szewczuk, M.R. (2016). Role of glycosylation in TOLL-like receptor activation and pro-inflammatory responses. Editor Wiederschain, Gherman. Glycobiology and Diseases. 1-18. Publisher Taylor & Francis/CRC Press Publishing House.

Selected Publications

2024

Nicole Mendonza 1, †, Daniel Leon Moshe 2, †, Yunfan Li 3, †, Emilyn Aucoin 4, †, Reza Bayat Mokhtari 5, 6, †, Daniella Ghokasian 2, †, Leili Baghaie 5, William W. Harless 7, Sayan Chakraborty 6, Cecile Malardier-Jugroot 1, *, and Myron R. Szewczuk 5, *. Next Generation of Nanomedicine for Novel Cancer Therapies: Functionalized Folate Amphiphilic Alternating Copolymer Immobilizes Folate Receptor Functionality in Disabling Key Survival Pathways Critical for Pancreatic Tumor Progression and Metastases. Vaccines 2024, 12(9), xxxx; https://doi.org/10.3390/vaccinesxxxx (Impact Factor: 5.2, indexed in PubMed). Special issue, “Cancer Vaccines and Combination Immunotherapies.” Under peer-review.
David A. Bunsick 1, †, Leili Baghaie 1, †, Yunfan Li 2, Abdulrahman M. Yaish 3 , Emilyn B. Aucoin 4 , Elizabeth Skapinker 2, Rashelle Aldbai 1, and Myron R. Szewczuk1, * . Synthetic CB1 Cannabinoids Surreptitiously Orchestrate Tunneling Nanotubes to Enhance Cancer Metabolic Drivers to Stage Migratory Intercellular Communication in Promoting Scratch Wound Migration and Epithelial–Mesenchymal Transition in Pancreatic PANC-1 and Colorectal SW-620 Cancer Cell Lines. Cells 2024, 13, xxxx. https://doi.org/10.3390/cellsxxxx (Impact factor 6.7, CiteScore 9.0, indexed in PubMed). Special issue topic: Cellular and Molecular Mechanisms of Cancer Invasion and Metastasis. under peer-review.
Emilyn B. Aucoin 1, †, Elizabeth Skapinker 2, †, Abdulrahman M. Yaish 3 , Yunfan Li 2, Haley L. Kombargi 3 , Daniel Jeyaraj 3 , Pankaj Garg 5, 6, Nicole Mendonza 4, Cecile Malardier-Jugroot 4, * and Myron R. Szewczuk 5, *. Glycosyl Mobile Radical Structures of Folic Acid Receptors Impact the Internalization of Functionalized Folate Amphiphilic Alternating Copolymer on Cancer Cells. Receptors 2024, 3(4), 457-473; https://doi.org/10.3390/receptors3040023. 1. Faculty of Science, Biology (Biomedical Science), York University, Toronto, ON M3J 1P3, Canada; 2. Faculty of Arts and Science, Queen’s University, Kingston, ON K7L 3N9, Canada; 3. Faculty of Health Sciences, Queen’s University, Kingston, ON K7L 3N9, Canada; 4. Department of Biomedical & Molecular Sciences, Queen’s University, Kingston, ON K7L3N6, Canada; 5. Toulouse Graduate School of Cancer Ageing and Rejuvenation (CARe), Université Toulouse III-Paul Sabatier, 31400 Toulouse, France; 6. Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON K7K 7B4, Canada; * Authors to whom correspondence should be addressed. † These authors contributed equally to this work
Elizabeth Skapinker 1,†, Emilyn B. Aucoin 2,†, Haley L. Kombargi 3, Abdulrahman M. Yaish 3, Yunfan Li 1, Leili Baghaie 4 and Myron R. Szewczuk 4,*. Contemporaneous Inflammatory, Angiogenic, Fibrogenic and Angiostatic Cytokine Profiles of the Time-to-Tumor Development by Cancer Cells to Orchestrate Tumor Neovascularization, Progression, and Metastatsis. Cells 2024, 13, 1739. https://doi.org/10.3390/cells13201739. Impact Factor: 5.1 (2023); 5-Year Impact Factor: 6.0 (2023). Special issue topic: Inflammatory Tumor Immune Microenvironment.
Rashelle Aldbai 1,2, Leili Baghaie 1, David A. Bunsick 1, Emilyn Aucoin 3, Yunfan Li 4, Daniella Ghokasian 2, and Myron R Szewczuk 1,* Cutting-Edge Approach to Targeted Therapy: Repositioning of Old Drugs in Combination with Standard Clinical Chemotherapeutics Potentiates a Propitious Novel Targeted Therapy for Human Pancreatic Cancer. SQU Journal for Science, Sultan Qaboos University, 2024, 29(2), 34-44. Received 27 March 2024; Received revised 14 January 2024; Accepted 14 January 2024. Special Issue Symposium “The Second Biotechnology Meeting - Biomedical Research and Medical Biotechnology.”
David A. Bunsick 1 , Jenna Matsukubo 1,2 , Rashelle Aldbai 1, Leili Baghaie 1 and Myron R. Szewczuk 1,*. (2024) Functional Selectivity of Cannabinoid Type 1 G Protein-Coupled Receptor Agonists in Transactivating Glycosylated Receptors on Cancer Cells to Induce Epithelial–Mesenchymal Transition Metastatic Phenotype. Cells 2024, 13, 480. https://doi.org/10.3390/cells13060480 (Impact factor 6.7, CiteScore 9.0, indexed in PubMed).
Junsu Lee 1, Hyunmin Lee 1, Adham El Sherbini 1, Leili Baghaie 2, Fleur Leroy 2,3, Husam Abdel-Qadir 4, Myron R. Szewczuk 2, and Mohammad El-Diasty 5,6, *. (2024) Epigenetic MicroRNA as Prognostic Markers of Post-Operative Atrial Fibrillation: A Systematic Review. Current Problems in Cardiology Volume 49, Issue 1, Part C, January 2024, 102106. 49(1)
Elizabeth Skapinker 1,†, Rashelle Aldbai 1,2,†, Emilyn Aucoin 3,†, Elizabeth Clarke 1, Mira Clark 4, Daniella Ghokasian 1, Haley Kombargi 1, Merlin J. Abraham 1, Yunfan Li 4, David A. Bunsick 2, Leili Baghaie 2 and Myron R. Szewczuk 2,*. Artificial and Natural Sweeteners Biased T1R2/T1R3 Taste Receptors Transactivate Glycosylated Receptors on Cancer Cells to Induce Epithelial–Mesenchymal Transition of Metastatic Phenotype. Nutrients 2024, 16, 1840. https://doi.org/10.3390/nu16121840. (Impact factor: 5.9, CiteScore 9.2, indexed in PubMed). Submission received: 22 April 2024 / Revised: 3 June 2024 / Accepted: 7 June 2024 / Published: 12 June 2024. Special Issue on the “Effects of Sugars and Sugar Alternatives on Human Health and Disease.”

2023

David A. Bunsick 1, Jenna Matsukubo 1,2, Rashelle Aldbai 1, Leili Baghaie 1 and Myron R. Szewczuk 1, *. Article. Functional Selectivity of Cannabinoid CB1 GPCR Agonists Transactivates Glycosylated Receptors on Cancer Cells to Induce E.M.T. Metastatic Phenotype. Cells 2023,12, xxxx; https://doi.org/10.3390/cells, xxxx- (Impact factor 6.7, Citescore 9.0, indexed in PubMed). Under peer-review. 1 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; 17dab5@queensu.ca (D.A.B.), 18jem9@queensu.ca (J.M.), 19ra57@queensu.ca (R.A.), 16lbn1@queensu.ca (L.B.), 2 Undergraduate Medical Education, Faculty of Medicine, University of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, ON K1H 8M5, Canada. * Correspondence: (M.R.S.) szewczuk@queensu.ca; Tel: +1-613-770-6403
Leili Baghaie 1, †, Fiona Haxho 1, 2, †, Fleur Leroy 1, 3, †, Beth Lewis 4, Alexander Wawer 4, Shamano Minhas 4, William W. Harless 4,*, and Myron R. Szewczuk 1, *. Contemporaneous Perioperative Inflammatory and Angiogenic Cytokine Profiles of Surgical Breast, Colorectal and Prostate Cancer Patients: Clinical Implications. Cells 2023, 12, 2767. https://doi.org/10.3390/cells12232767 (Impact factor: 6.0, citescore 9.0, indexed in PubMed). Section: Cellular Pathology, Special Issue: Tumor Immune Microenvironment for Effective Therapy II. Received Date 8 November 2023, Revised Date 29 November 2023, Accepted Date 2 December 2023. 1 Department of Biomedical & Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; 16lbn1@queensu.ca; szewczuk@queensu.ca; 2 Dermatology Residency Program, the Cumming School of Medicine, University of Calgary, Calgary, T2T 5C7, Canada. fiona.haxho@mail.utoronto.ca; 3 Faculté de médecine, Maïeutique et Sciences de la Santé, Université de Strasbourg, F-67000 Strasbourg, France; fleur.leroy@etu.unistra.fr or 23rgt@queensu.ca; 4 ENCYT Technologies Inc., Membertou, NS B1S 0H1, Canada ; blewis@encyt.net ; alexwawer@gmail.com ; shamano12@hotmail.com ; wharless@encyt.net; * Correspondence: szewczuk@queensu.ca ; wharless@encyt.net . † These authors contributed equally to this work. All the authors acknowledge the educational and scholarly alliance of the Health Sciences Graduate Program in Experimental Medicine at Queen’s University, the Faculté de Médecine, Maïeutique et Sciences de la Santé, Université de Strasbourg, F-67000 Strasbourg, France and the expert technical research team at ENCYT Technologies Inc.
Junsu Lee 1, Hyunmin Lee 1, Adham El Sherbini 1, Leili Baghaie 2, Fleur Leroy 2,3, Husam Abdel-Qadir 4, Myron R. Szewczuk 2, and Mohammad El-Diasty 5,6, * Epigenetic MicroRNA as Prognostic Markers of Post-Operative Atrial Fibrillation: A Systematic Review. Current Problems in Cardiology, Volume 49, Issue 1, Part C, January 2024, 102106, https://doi.org/10.1016/j.cpcardiol.2023.102106. (Impact Factor: IF 4.2) 1 Faculty of Health Sciences, Queen’s University, Kingston, ON, Canada. 20jl193@queensu.ca, emily.lee@queensu.ca, adham.elsherbini@queensu.ca 2 Department of Biomedical & Molecular Sciences, Queen’s University, Kingston, ON, Canada; LB 16lbn1@queensu.ca; MRS, szewczuk@queensu.ca. 3 Faculté de Médecine, Maïeutique et Sciences de la Santé, Université de Strasbourg, F-67000 Strasbourg, France; fleur.leroy@etu.unistra.fr or 23rgt@queensu.ca 4 Women’s College Hospital, Peter Munk Cardiac Center, 585 University Ave, Toronto, ON M5G 2N2. h.abdel.qadir@utoronto.ca 5 Division of Cardiac Surgery, Kingston Health Sciences Centre, Queen’s University, 76 Stuart St, Kingston (ON), K7L2V7, Canada. cardiac.science.lab@gmail.com or mohammad.eldiasty@kingstonhsc.ca. 6 Harrington Heart and Vascular Institute, Department of Cardiac Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, U.S.A. cardiac.science.lab@gmail.com. * Corresponding author: M. El-D. cardiac.science.lab@gmail.com or mohammad.eldiasty@kingstonhsc.ca
Daniel Leon Moshe 1,‡, Leili Baghaie 2.,‡, Fleur Leroy 3, Elizabeth Skapinker 4 and Myron R. Szewczuk 1,*. Metamorphic Effect of Angiogenic Switch in Tumor Development: Conundrum of Tumor Angiogenesis Toward Progression and Metastatic Potential. Biomedicines 2023, 11(8), 2142. https://doi.org/10.3390/biomedicines11082142. Received: 29 June 2023 / Revised: 27 July 2023 / Accepted: 28 July 2023 / Published: 29 July 2023 (This article belongs to the Special Issue Angiogenic Growth Gactors in Tumor Development: Beyond New Blood Vessels Formation) (Impact Factor: 4.7 (2022); 5-Year Impact Factor: 4.9 (2022); indexed in PubMed) Journal Rank: JCR - Q1 (Pharmacology & Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous)). 1 Faculty of Health Sciences, Queen’s University, Kingston, ON K7L 3N9, Canada; daniel.moshe@queensu.ca (DLM). 2 Department of Biomedical & Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; 16lbn1@queensu.ca (LB); szewczuk@queensu.ca (MRS). 3 Universite de Strasbourg, F-67000 Strasbourg, France fleur.leroy@etu.unistra.fr or 23rgt@queensu.ca (FL) 4 Faculty of Arts and Science, Queen’s University, Kingston, ON K7L 3N9, Canada; 21ess18@queensu.ca (ES). ‡ Contributed equally as first authors. * Correspondence: szewczuk@queensu.ca (MRS)
Leili Baghaie 1, Fleur Leroy 2, Mehdi Sheikhi 3,4, Abdollah Jafarzadeh 5, Myron R. Szewczuk 1 and Abdolkarim Sheikhi 1,3, *. Review. Contemporaneous SARS-CoV-2 Neutralizing Antibodies Mediated by N-glycan Shields. Viruses 2023, 15(10), 2079. https://doi.org/10.3390/v15102079 (registering DOI), Received: 19 August 2023 / Revised: 3 October 2023 / Accepted: 9 October 2023 / Published: 12 October 2023. Journal Viruses, Section Viral Immunology, Vaccines, and Antivirals, Special Issue SARS-CoV-2: Vaccine Design and Host Immunity. Impact Factor: 4.7 (2022); 5-Year Impact Factor: 4.8 (2022). High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases. Journal Rank: JCR-Q2 (Virology) / CiteScore - Q! (Infectious Diseases) 1 Department of Biomedical & Molecular Sciences, Queen’s University, Kingston, ON, K7L 3N6, Canada; L.B. 16lbn1@queensu.ca; M.R.S. szewczuk@queensu.ca; AS sheikhi@queensu.ca; 2 Faculte de Medecine, Maieutique et Sciences de la Sante, Universite de Strasbourg, F-67000 Strasbourg, France; fleur.leroy@etu.unistra.fr or 23rgt@queensu.ca 3 Department of Immunology, School of Medicine, Dezful University of Medical Sciences 64616‐43993 Dezful, Iran. 4 Faculty of Medicine, Kazeroon Azad University, Kazeroon, Iran mehsha_2012@hotmail.com. 5 Department of Immunology, Medical School, Kerman University of Medical Sciences Kerman, Iran jafarzadeh14@yahoo.com. * Correspondence: A.S. sheikhi@queensu.ca.
Leili Baghaie †, David A. Bunsick † and Myron R. Szewczuk *. Editorial. Insulin Receptor Signaling in Health and Disease. Biomolecules 2023, 13(5), 807; https://doi.org/10.3390/biom13050807 (registering DOI). Received: May 6, 2023 / Accepted: May 8, 2023 / Published: May 9, 2023—Special Issue 100th Anniversary of Insulin: Insulin Receptor Signaling in Health and Disease.
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada. * Author to whom correspondence should be addressed. † These authors contributed equally to this work.
Jenna Matsukubo †, David A. Bunsick † and Myron R. Szewczuk *. Review Cannabinoid CB1 Functional Selectivity Transactivate Glycosylated Receptors in Health and Disease. Cells 2023,12, xxxx; https://doi.org/10.3390/cells, xxxx. Under peer review May 9, 2023 (impact factor: 7.666, cite score 6.7, indexed PubMed) Section: Cell Signaling, Special Issue: Novel Insights into Cannabinoid Receptors, Molecular Targets, and Therapeutic Potentials. Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; 18jem9@queensu.ca (J.M.); 17dab5@queensu.ca (D.A.B.). * Correspondence: szewczuk@queensu.ca; Tel: +1-613-770-6403. † These authors contributed equally to this work.
Reza Bayat Mokhtari 1,2, Neda Ashayeri 3‡, Leili Baghaie 2‡, Manpreet Sambi 2‡, Kosar Satari3, Narges Baluch 4, Dmitriy A. Bosykh 1, Myron R Szewczuk 2, and Sayan Chakraborty 1*. The Hippo pathway effectors YAP/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment. Cancers 2023, 15(13)3468, https://doi.org/10.3390/cancers15133468; Special Issue New Insights on the Hippo-YAP/TAZ-TEAD Pathway and Its Roles in Cancer (Impact factor: 6.886 (2021), CiteScore- Q! (Oncology), indexed PubMed), submitted for consideration for publication, May 8, 2023; Revised 7 June 2023; accepted 21 June 23. 1 Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, U.S.A. 2 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada. 3 Division of Hematology and Oncology, Department of Pediatrics, Ali-Asghar Children Hospital, Iran University of Medical Science, Tehran, Iran. 4 Department of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada. ‡ Equivalent second contributing authors *Corresponding author: Sayan Chakraborty; Email: Sayan.Chakraborty@RoswellPark.org
William Khoury ¹, Ryan Trus ^2,3, Amy Xingyu Chen ¹, Leili Baghaie ⁴, Mira Clark ^2,4, Myron R. Szewczuk ^{4, *}, Mohammad El-Diasty ^{5, *}Review: Parsimonious Effect of Pentoxifylline on Angiogenesis: A Novel Pentoxifylline Biased Adenosine G Protein-Coupled Receptor Signaling Platform. Cells 2023, 12, 1199. https://doi.org/10.3390/cells12081199. Impact Factor: 7.666 (2021); 5-Year Impact Factor: 7.677 (2021), High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases, Journal Rank: JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology). ¹School of Medicine, Queen’s University, Kingston, ON, Canada. W.K. wkhoury@qmed.ca, A.X.C. amy.chen@queensu.ca; ² Faculty of Arts and Science, Queen’s University, Kingston, ON, Canada. ³ School of Medicine, The Larner College of Medicine, University of Vermont, Burlington, VT, U.S.A. R.T. ryan.trus@med.uvm.edu; ⁴Department of Biomedical & Molecular Sciences, Queen’s University, Kingston, ON, Canada; L.B.N. 16lbn1@queensu.ca; MC 21myjc@queensu.ca; M.R.S. szewczuk@queensu.ca ⁵Division of Cardiac Surgery, Queen’s University, Kingston, ON, Canada; M.E-D. mohammad.eldiasty@kingstonhsc.ca; ^*Corresponding authors: mohammad.eldiasty@kingstonhsc.ca or szewczuk@queensu.ca
William W. Harless 1, *, Bessi Qorri 2, Samar Abdulkhalek 3 and Myron R. Szewczuk 2, * Novel Therapeutic Target Critical for COVID-19 Infectivity and Cytokine Release Storm. Cells 2023, 12(9), 1332; https://doi.org/10.3390/cells12091332 (impact factor: 7.666, Cite score: 6.7, indexed in PubMed), Research Article, Section: Cellular Pathology, Special Issue: Angiotensin-Converting Enzyme 2 in Health and Diseases, Accepted: April 28, 2023; Received: February 2, 2023. 1 ENCYT Technologies Inc., Membertou, Nova Scotia, B1S 0H1, Canada. 2 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, K7L 3N6, Canada. bessi.qorri@queensu.ca. 3 Higher Colleges of Technology, Faculty of Health Sciences, Abu Dhabi, United Arab Emirates. sabdulkhalek@hct.ac.ae, * Correspondence: wharless@encyt.net (W.W.H.) ; szewczuk@queensu.ca (M.R.S.); Tel.: +1-902-574-3540 (W.W.H.); +1-613-770-6403 (M.R.S.)
David A. Bunsick, 1, 2, * Jenna Matsukubo, 1, * and Myron R. Szewczuk2,3, #. Cannabinoids Transmogrify Cancer Metabolism and Epigenetic Reprogramming using a Novel Biased G Protein-coupled Receptor Signaling Platform. Cancers 2023, 15(4), 1030; https://doi.org/10.3390/cancers15041030 . (Impact factor 6.575, indexed PubMed). After extensive peer review from experts in the field. Received: 7 January 2023, Accepted: 03 February 2023. Academic Editors: Kenta Masui and Linlin Guo. 1 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario K7L3N6, Canada. D.A.B. 17dab5@queensu.ca; J.M. 18jem9@queensu.ca. 2 ORCID https://orcid.org/0000-0002-7050-5042 ; 3 ORCID https://orcid.org/0000-0001-8471-5481 ;* Contributing to first authorships. # Correspondence: Dr. Myron R. Szewczuk, szewczuk@queensu.ca . All authors acknowledge the educational and scholarly alliance of the Graduate Program in Experimental Medicine and the Health Sciences, HSCI BHSc Research program.
Merlin Jesso Abraham1, Adham El Sherbini1, Mohammad El-Diasty2, Sussan Askari3 and Myron R. Szewczuk1,* Restoring Epigenetic Reprogramming with Diet and Exercise to Improve Health-related Disorders. Biomolecules 2023, 13, 318. https://doi.org/10.3390/biom13020318. (5-year Impact Factor: 6.191, CiteScore 5.7, indexed in PubMed) after extensive peer review from experts in the field. Academic Editor(s): Shang-Zhong Xu; Thozhukat Sathyapalan. Received: 17 January 2023, Revised: 30 January 2023, Accepted: 03 February 2023. 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada, 2Department of Surgery, Kingston Health Science Centre, Queen’s University, Kingston, ON, Canada, 3Department of Physical Medicine and Rehabilitation, Queen’s University, Kingston, ON, Canada. Acknowledgment: the educational and scholarly alliance of the Health Sciences, Faculty Development mentorship program, Office of Professional Development & Educational Scholarship (M. El-Diasty, M.D., Ph.D. and S. Askari, M.D.), and the Health Sciences, HSCI BHSc Research program (M.J. Abraham and A. El Sherbini).

2022

William W. Harless 1, *, Bessi Qorri 2, Samar Abdulkhalek 3 and Myron R. Szewczuk 2, * Novel Therapeutic Target Critical for COVID-19 Infectivity and Cytokine Release Storm. 2022 Science (impact factor: 47.728, indexed in PubMed), Research Article COVID-19, manuscript submitted for consideration for publication, December 09, 2022. 1 ENCYT Technologies Inc., Membertou, Nova Scotia, B1S 0H1, Canada. 2 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, K7L 3N6, Canada. bessi.qorri@queensu.ca, 3 Higher Colleges of Technology, Faculty of Health Sciences, Abu Dhabi, United Arab Emirates. sabdulkhalek@hct.ac.ae, * Correspondence: wharless@encyt.net (W.W.H.) ; szewczuk@queensu.ca (M.R.S.); Tel.: +1-902-574-3540 (W.W.H.); +1-613-533-2457 (office) or +1-613-770-6403 (mobile) (M.R.S.)
Merlin Jesso Abraham1, Adham El Sherbini1, Mohammad El-Diasty2, Sussan Askari3 and Myron R. Szewczuk1,* Restoring Epigenetic Reprogramming with Diet and Exercise to Improve Health-related Disorders. Frontiers in Nutrition, a section of Nutrition and Metabolism, doi: 10.3389/fnut.xxxx (impact factor: 6.590, indexed PubMed), submitted for consideration for publication, December 07, 2022. 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada, 2Department of Surgery, Kingston Health Science Centre, Queen’s University, Kingston, ON, Canada, 3Department of Physical Medicine and Rehabilitation, Queen’s University, Kingston, ON, Canada. Acknowledgement: the educational and scholarly alliance of the Health Sciences, Faculty Development mentorship program, Office of Professional Development & Educational Scholarship (M. El-Diasty, M.D., Ph.D. and S. Askari, M.D.), and the Health Sciences, HSCI BHSc Research program (M.J. Abraham and A. El Sherbini).
Sirin A Adham1,*, Myron R. Szewczuk2, Fatima Mraiche3, Emanuel Petricoin4. Editorial: Recent Advancements in Neoadjuvant Chemotherapy for Specific Breast Cancer Subtypes. Frontiers in Oncology, section Breast Cancer 2022, 12:1100427. doi: 10.3389/fonc.2022.1100427, accepted for publication November 23, 2022. (Impact Factor: 6.244 (2022), indexed PubMed). 1 Department of Biology, College of Science, Sultan Qaboos University, P. O. Box 36, 123, Muscat, Oman. 2 Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L3N6, Canada. Email: szewczuk@queensu.ca; 3 College of Pharmacy, QU Health, Qatar University, PO Box 2713, Doha, Qatar, Biomedical and Pharmaceutical Research Unit, Qatar University, Doha, Qatar. Email: fatima.mraiche@qu.edu.qa. 4 Institute for Biomedical Innovation, George Mason University, 10920 George Mason Circle, Manassas, VA 20110. Email: epetrico@gmu.edu. *Corresponding author: E-mail: sadham@squ.edu.om; sirinadham@yahoo.com; Telephone (office): + 968 24146869; Mobile phone: + 968 99417534; Fax: + 968 24146873
Bessi Qorri 1, Reza Bayat Mokhtari 1, William W. Harless 2,* and Myron R. Szewczuk 1,*. Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases. Cancers 2022, 14, 3595, https://doi.org/10.3390/cancers14153595 (5-Year Impact Factor: 6.886 (2021), indexed PubMed), Received Date: 2 July 2022, Revised Date: 18 July 2022, Accepted Date: 21 July 2022, Published Date: 23 July 2022. 1 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; bessi.qorri@queensu.ca (B.Q.); reza.bayatmokhtari@sickkids.ca (R.B.M.), 2 ENCYT Technologies Inc., Membertou, NS B1S 0H1, Canada, * Correspondence: wharless@encyt.net (W.W.H.); szewczuk@queensu.ca (M.R.S.); Tel.: +1-902-574-3540 (W.W.H.); +1-613-533-2457 (office) or +1-613-770-6403 (mobile) (M.R.S.)
Bessi Qorri1, Reza Bayat Mokhtari1, William W. Harless2,* and Myron R. Szewczuk1,* Drug repurposing in cancer therapy: aspirin and oseltamivir phosphate in combination with gemcitabine actively target the PI3K/Akt/mTOR survival pathways and disable hypoxia and the epithelial-to-mesenchymal transition to reduce cancer stem cells in pancreatic cancer. Cancers 2022, 14, x. (Impact factor 6.639, 2022, indexed PubMed), submitted March 19, 2022. 1 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; bessi.qorri@queensu.ca (B.Q.); reza.bayatmokhtari@sickkids.ca (R.B.M.). 2 ENCYT Technologies Inc., Membertou, NS B1S 0H1, Canada. *Correspondence: wharless@encyt.net (W.W.H.); szewczuk@queensu.ca (M.R.S.); Tel.: +1-902-574-3540 (W.W.H.); Tel.: +1-613-533-2457 (M.R.S.); Fax: +1-613-533-6796 (M.R.S.)
Bessi Qorri1, Reza Bayat Mokhtari1, William W. Harless2,*, and Myron R. Szewczuk1,*. Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression. Cancers 2022, 14, 1374 (Impact factor 6.639, 2022, indexed PubMed), https://doi.org/10.3390/cancers14061374. 1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; 2ENCYT Technologies Inc., Membertou, Nova Scotia, B1S 0H1, Canada. *Correspondences: William Harless, MD, Ph.D. and CEO of ENCYT Technologies Inc., Membertou, Nova Scotia, B1S 0H1, Canada: Tel +1 902 574 3540; Email: harless@encyt.net; Myron R Szewczuk, Ph.D., Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; Tel +1 613 533 2457; Fax +1 613 533 6796; Email: szewczuk@queensu.ca

2021

Nurul Shahfiza Noor1, Noor Haida Mohd Kaus2, Myron R. Szewczuk3 and Shahrul Bariyah Sahul Hamid 1,*. Formulation, characterization and cytotoxicity effects of the novel thymoquinone-PLGA-PF68 nanoparticles. Int. J. Mol. Sci. 2021, 22, 9420. https://doi.org/10.3390/i jms22179420. (impact factor: 5.923; indexed in PubMed). Submitted for publication 29 July 2021. Accepted for publication 26 August 2021. 1 Oncological and Radiological Sciences Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Penang, Malaysia; nurulshahfiza@gmail.com; 2 Department of Physical Chemistry, School of Chemical Sciences, Universiti Sains Malaysia, Penang, Malaysia; noorhaida@usm.my; 3Department of Biomedical and Molecular Sciences, Kingston, Ontario, Canada; szewczuk@queensu.ca. *Correspondence: shahrulbariyah@usm.my
Reza Bayat Mokhtari ^1,2,*,†, Manpreet Sambi ^1,†, Bessi Qorri ¹, Narges Baluch ³, Neda Ashayeri ⁴, Sushil Kumar ⁵, Hai-Ling Margaret Cheng ^6,7, Herman Yeger ⁸, Bikul Das ^2,9 and Myron R. Szewczuk ^1,*. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers 2021, 13, 3596. https://doi.org/10.3390/cancers13143596. (Impact factor: 6.639, indexed PubMed) Received: 14 June 2021; Accepted: 14 July 2021; Published: 18 July 2021. ¹ Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; 13ms84@queensu.ca (M.S.); bessi.qorri@queensu.ca (B.Q.); ² Department of Experimental Therapeutics, Thoreau Laboratory for Global Health, M2D2, University of Massachusetts, Lowell, MA 01852, U.S.A.; bdas@kavikrishnalab.org; ³ Department of Immunology and Allergy, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada; Narges.baluch@sickkids.ca; ⁴ Division of Hematology & Oncology, Department of Pediatrics, Ali-Asghar Children Hospital, Iran University of Medical Science, Tehran 1449614535, Iran; Ashayeri.n@iums.ac.ir; ⁵ Q.P.S., Holdings L.L.C., Pencader Corporate Center, 110 Executive Drive, Newark, DE 19702, U.S.A.; sushilkumar29@yahoo.ca; ⁶ The Edward S. Rogers Sr. Department of Electrical & Computer Engineering, Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5G 1M1, Canada; hailing.cheng@utoronto.ca; ⁷ Translational Biology & Engineering Program, Ted Rogers Centre for Heart Research, University of Toronto, Toronto, ON M5G 1M1, Canada; ⁸ Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada; hermie@sickkids.ca; ⁹ KaviKrishna Laboratory, Department of Cancer and Stem Cell Biology, GBP, Indian Institute of Technology, Guwahati 781039, India; * Correspondence: rbm7@queensu.ca (R.B.M.); szewczuk@queensu.ca (M.R.S.); † Co-First/Equal authorship: These authors contributed equally to this work.
Reza Bayat Mokhtari^1,2,9,*, Bessi Qorri², Narges Baluch³, Angelo Sparaneo⁴, Federico Pio Fabrizio⁴, Lucia Anna Muscarella⁴, Albina Tyker⁵, Sushil Kumar⁶, Hai-Ling Margaret Cheng⁷, Myron R Szewczuk^2,*, Bikul Das^8,9,10 and Herman Yeger^1,* Next-Generation Multimodality of Nutrigenomic Cancer Therapy: Sulforaphane in Combination with Acetazolamide Actively Target Bronchial Carcinoid Cancer in Disabling PI3K/Akt/mTOR Survival Pathway and Inducing Apoptosis. 2021 Oncotarget (Impact Factor 5.126, indexed PubMed) submitted for publication Date 28 May 2021, accepted for publication June 12, 2021 after extensive peer review. ¹Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada. ² Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada. ³Department of Pediatrics, Queen’s University, Kingston, Ontario, Canada. ⁴Laboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, viale Cappuccini, San Giovanni Rotondo (FG), Italy. ⁵ Department of Internal Medicine University of Chicago, Chicago, U.S.A. ⁶ Q.P.S. Holdings LLC, Pencader Corporate Center, Newark, Denver, U.S.A. ⁷ Institute of Biomedical Engineering, The Edward S. Rogers Sr. Department of Electrical & Computer Engineering, University of Toronto, Canada. ⁸ Department of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Guwahati Biotech Park, Indian Institute of Technology, Guwahati, Assam, India. ⁹ Department of Experimental Therapeutics, Thoreau Laboratory for Global Health, M2D2, University of Massachusetts, Lowell, Massachusetts, USA. ¹⁰ Department of Immunology and Infectious Diseases, Forsyth Institute, Cambridge, Massachusetts, USA.
Reza Bayat Mokhtari^1,2,‡, Bessi Qorri¹, Manpreet Sambi¹, Narges Baluch³, Sushil Kumar⁴, Bikul Das^2,5, Myron Szewczuk^1,‡, Herman Yeger^6,‡, Hai-Ling Margaret Cheng^7,‡ 3D Multicellular Stem-like Human Breast Tumor Spheroids Enhance Tumorigenicity of Orthotopic Xenografts in Athymic Nude Rat Model. 2021 Cancers 13(11), 2784 (Impact Factor 6.126, indexed PubMed) https://doi.org/10.3390/cancers13112784 ->submitted for publication Date 8 May 2021, Revised Date 21 May 2021, Accepted Date 28 May 2021 after extensive peer-review. ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada. ²Department of Experimental Therapeutics, Thoreau Laboratory for Global Health, M2D2, University of Massachusetts, Lowell, Massachusetts, U.S.A. ³Department of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada. ⁴QPS. Holdings LLC, Pencader Corporate Center, 110 Executive Drive, Newark, Delaware, U.S.A. ⁵Department of Cancer and Stem Cell Biology and Department of Experimental Therapeutics, Thoreau Lab for Global Health, University of Massachusetts-Lowell, Lowell, Massachusetts, U.S.A. ⁶Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada. ⁷Institute of Biomedical Engineering, The Edward S. Rogers Sr. Department of Electrical & Computer Engineering, University of Toronto; Translational Biology & Engineering Program, Ted Rogers Centre for Heart Research, Canada
Alexandria DeCarlo¹, Cecile Malardier-Jugroot^2,*,and Myron R. Szewczuk^1,* Folic Acid-Functionalized Nanomedicine: Folic Acid Conjugated Copolymer and Folate Receptor Interactions Disrupt Receptor Functionality Resulting in Dual Therapeutic Anti-Cancer Potential in Breast and Prostate Cancer. 2021 Bioconjugate Chemistry 32, 3, 512–522 (Impact Factor 4.6, indexed PubMed). https://doi.org/10.1021/acs.bioconjchem.0c00625 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada. ²Department of Chemistry and Chemical Engineering, VP Research, Royal Military College of Canada, Kingston, ON, Canada.

2020

Bessi Qorri¹, William Harless², and Myron R Szewczuk¹. Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells. 2020 Drug Design, Development and Therapy, 14: 4149–4167. DOI https://doi.org/10.2147/DDDT.S264122 (Impact factor 3.208, indexed PubMed), ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²Encyt Technologies, Inc., Membertou, NS, Canada.
Alexandria DeCarlo¹, Cecile Malardier-Jugroot^2,*,and Myron R. Szewczuk^1,*Next-Generation Multimodality of Nanomedicine Therapy: Folic Acid Conjugated Copolymer and Folate Receptor Interactions Disrupt Receptor Functionality Resulting in Dual Therapeutic Anti-Cancer Potential in Triple-Negative Breast Cancer. 2020 Cancers (Impact Factor 6.126, indexed PubMed) submitted for publication on August 10, 2020. ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada. ²Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON, Canada.
Manpreet Sambi¹, Vanessa Samuel², Bessi Qorri¹, Sabah Haq³, Sergey V. Burov⁴, Elena Markvicheva⁵, William Harless⁴, and Myron R. Szewczuk^1,*. A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Significantly Impacts Tumor Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. 2020 Drug Design, Development and Therapy 14 1995–2019 (Impact factor 3.208, indexed PubMed). ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; ³Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; ⁴Laboratory of Novel Peptide Therapeutics, Cytomed J.S.Co., St-Petersburg, Russia; ⁵Biomedical Materials Laboratory, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; ⁴Encyt Technologies, Inc., Membertou, NS, Canada.

2019

Regina-Veronicka Kalaydina¹, Hedi Zhou¹, Elena Markvicheva², Sergey V Burov³, Farhana Zulkernine⁴, and Myron R Szewczuk^1,*. Impact of fucosylation on self-assembly of prostate and breast tumor spheroids by using cyclo-RGDfK(TPP) peptide and image object detection. 2019 OncoTargets and Therapy 12, 11153–11173 (Impact factor 3.046, indexed PubMed). ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada; ²Biomedical Materials Laboratory, Shemyakin-Ovchinnikov, Institute of Bioorganic Chemistry, Russia, Moscow, Ul. Miklukho-Maklaya 16/10; ³Laboratory of Novel Peptide Therapeutics, Cytomed J.S.Co., St-Petersburg, Russia; ⁴School of Computing, Queen’s University, Kingston, ON. Canada.
Manpreet Sambi¹, Alexandria DeCarlo¹, Cecile Malardier-Jugroot^2,* and Myron R. Szewczuk^1,*. Next-Generation Multimodality of Nanomedicine Therapy: Size and Structure Dependence of Folic Acid Conjugated Copolymers Actively Target Cancer Cells in Disabling Cell Division and Inducing Apoptosis. Cancers 2019, 11, 1698; doi:10.3390/cancers11111698. (Impact factor 6.1, indexed PubMed), (Special Issue Cancer Nanomedicine). ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada; ²Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON K7K 7B4, Canada. https://doi.org/10.3390/cancers11111698
Manpreet Sambi¹, Leila Bagheri^1,2 and Myron R Szewczuk¹. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates. 2019 Journal of Oncology, Volume 2019, Article ID 4508794, 12 pages, (Open Special Issue-Immunotherapy), (Impact factor: 4.528; indexed PubMed), ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²Present address: Postdoctoral Fellow, Research Laboratories in Sciences, Applied to Food, Canadian Irradiation Center, Universite du Quebec, INRS-Institue Armand-Frappier, 531, boul. des Prairies, Laval, QC, H7V 1B7, Canada. https://doi.org/10.1155/2019/4508794
Iryna Liauchonak^1,4, Bessi Qorri^2,4, Fady Dawoud¹, Yatin Riat^1,3,4, and Myron R. Szewczuk^2,*. Non-nutritive Sweeteners and their Implications on the Development of Metabolic Syndrome. Nutrients 2019, 11, 644. (Impact factor 4.6, indexed PubMed). ¹Graduate Diploma and Professional Master in Medical Sciences, Postgraduate Medical Education, School of Medicine, Queen’s University, Kingston, ON, Canada; ²Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ³Present address: Emergency Medicine, Resident Physician, Brooklyn Hospital Centre, 121 DeKalb Avenue, Brooklyn, N.Y. 11201, USA. ⁴Contributing first authorship http://dx.doi.org/10.3390/nu11030644 &nbsp
Justin Jain^1,*, Bessi Qorri^2,* and Myron R Szewczuk². The Crucial Role of Primary Care Providers in the Long-term follow up of Adult Survivors of Childhood Cancer. Cancer Management and Research 2019:11 3411–3418. (Impact factor 3.702, indexed PubMed). ¹Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; ²Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; *Contributing first authorship https://doi.org/10.2147/CMAR.S197644

2018

Bessi Qorri¹, Regina-Veronicka Kalaydina¹, Aleksandra Velickovic¹, Yekaterina Kaplya¹, Alexandria Decarlo² and Myron R. Szewczuk¹. Agonist-biased signaling via matrix metalloproteinase-9 promotes extracellular matrix remodeling. Cells 2018, 7, 117 (Impact factor 4.829; indexed in PubMed). ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²Department of Biology, Biosciences Complex, Queen’s University, Kingston, ON, Canada K7L 3N6. http://dx.doi.org/10.3390/cells7090117
Regina-Veronicka Kalaydina^1,4, Komal Bajwa^2,4, Bessi Qorri^1,4, Alexandria Decarlo³ and Myron R. Szewczuk¹. Recent advances in “smart” delivery systems for extended drug release in cancer therapy. International Journal of Nanomedicine 2018:13 4727–4745. (Impact factor: 5.008, indexed in PubMed). ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; ³Department of Biology, Queen’s University, Kingston, ON, Canada; ⁴Contributing first authorship https://doi.org/10.2147/IJN.S168053.
Xia Li^1,6, Manpreet Sambi^2,6, Alexandria DeCarlo³, Sergey V Burov⁴, Roman Akasov⁵, Elena Markvicheva⁵, Cecile Malardier-Jugroot¹ and Myron R Szewczuk². Functionalized folic acid-conjugated amphiphilic alternating copolymer actively targets 3D multicellular tumor spheroids and delivers the hydrophobic drug to the inner core. Nanomaterials 2018, 8, 588. (Impact factor 4.358, indexed PubMed). ¹Department of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, ON, Canada; ²Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ³Department of Biology, Queen’s University, Kingston, ON, Canada; ⁴Synthesis of Peptides and Polymer Microspheres Laboratory, Institute Macromolecular Compounds, Russian Academy of Sciences, St Petersburg, Russia; ⁵Department of Biomaterials and Biotechnologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; ⁶Contributing first authors. doi:10.3390/nano8080588
Iryna Liauchonak, MD^1,3, Fady Dawoud, MBBCh^1,3, Yatin Riat, MD^1,3, Bessi Qorri^2,3, Manpreet Sambi^2,3, Justin Jain, MD¹, Regina-Veronicka Kalaydina², Nicole Mendonza², Komal Bajwa, MBBS¹, and Myron R. Szewczuk². Biased G-protein coupled receptor agonism bridges the gap between the insulin receptor and metabolic syndrome. Int. J. Mol. Sci. 2018, 19, 575. (Impact factor: 3.2; indexed in PubMed). ¹Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada; ²Department of Biomedical and Molecular Science, Queen’s University, Kingston ON, Canada; ³Contributing first authorship. https://doi:10.3390/ijms19020575
Kurt Wood¹, Myron R. Szewczuk², Dérick Rousseau³ and Ronald J. Neufeld¹. Oseltamivir phosphate released from injectable Pickering emulsions over extended term disables human pancreatic cancer cell survival. Oncotarget 2018, Vol. 9, (No. 16), pp: 12754-12768. (Impact factor 5.168, indexed in PubMed). ¹Chemical Engineering, Queen's University. ²Department of Biomedical and Molecular Science, Queen’s University, Kingston ON, Canada; ³Department of Chemistry and Biology, Ryerson University, Toronto, Ontario, Canada, M5B 2K3. https://doi.org/10.18632/oncotarget.24339
Fiona Haxho, Sabah Haq and Myron R. Szewczuk. Biased G protein-coupled receptor agonism mediates Neu1 sialidase and matrix metalloproteinase-9 cross-talk to induce transactivation of insulin receptor signaling. 2018 Cellular Signalling 43, 71-84 (Impact factor 4.2, indexed in PubMed). Department of Biomedical and Molecular Science, Queen’s University, Kingston ON, Canada https://doi.org/10.1016/j.cellsig.2017.12.006
Yara Mouhamed^1,3, Andrey Vishnyakov^1,3, Bessi Qorri^2,3, Manpreet Sambi^2,3, Signy Frank¹, Catherine Nowierski¹, Anmol Lamba¹, Umrao Bhatti¹, and Myron R Szewczuk². Therapeutic Potential of Medicinal Marijuana: An Educational Primer for Healthcare Professionals. 2018 Drug, Healthcare and Patient Safety 10: 45–66, (Indexed in PubMed Central PMID:29928146). ¹Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University. ²Department of Biomedical and Molecular Sciences, Queen’s University. ³Contributing first authorship. https://www.dovepress.com/therapeutic-potential-of-medicinal-marijuana-an-educational-primer-for-peer-reviewed-article-DHPS

2017

Myron R Szewczuk. Biased G protein-coupled receptor agonism and mammalian neuraminidase 1-mediated glycosylated receptor signaling platform. J Glycobiol 2017, 6:2(Suppl). Department of Biomedical and Molecular Sciences, Queen’s University. DOI: 10.4172/2168-958X-C1-008
Manpreet Sambi^1,#, Bessi Qorri^1,#, S. M. Signy Frank², Yara Mouhamed², Regina-Veronicka Kalaydina¹, Nicole Mendonza¹ and Myron R. Szewczuk^1,*. Novel Use of Peptides to Facilitate the Formation of 3D Multicellular Tumor Spheroids. 2017 Curr Top Pept Protein Res 18, 25-34. ¹Department of Biomedical and Molecular Sciences, Queen’s University. ²Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen’s University. ^#Contributing first authorship. http://www.researchtrends.net/tia/article_pdf.asp?in=0&vn=18&tid=26&aid…
Regina-Veronicka Kalaydina^1,2, Bessi Qorri^1,2, Myron R. Szewczuk¹. Preventing Negative Shifts in Gut Microbiota with Cannabis Therapy: Implications for Colorectal Cancer. Adv. Res. Gastroentero. Hepatol. 2017; 7(3): 555712.¹Department of Biomedical and Molecular Sciences, Queen’s University. ²contributing first authors. DOI: 004 10.19080/ARGH.2017.07.555712
Sabah Haq^1,2,3, Manpreet Sambi^1,3, Bessi Qorri^1,3, Nicole Mendonza^1,3and Myron R. Szewczuk¹. Aberrant Sialic Acid Expression and its Role in Regulating Metastasis in Colorectal Cancer. Adv Res Gastroentero Hepatol 2017; 7(2): 555707. ¹Department of Biomedical and Molecular Sciences, Queen's University, Canada; ²Department of Pathology and Molecular Medicine, McMaster University, Canada; ³Contributing first authorship. http://dx.doi.org/10.19080/argh.2017.07.555707
Bessi Qorri^1,2, Manpreet Sambi^1,2, Myron R. Szewczuk¹. Gut Microbiota and its Implications on the Progression of Gastrointestinal Cancer. Adv Res Gastroentero Hepatol 6(5):ARGH.MS.ID.555696 (2017). ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Canada. ²Contributing first authorship, Canada. http://dx.doi.org/10.19080/argh.2017.06.555696
Manpreet Sambi^1,2, Bessi Qorri^1,2, Cecile Malardier-Jugroot³, and Myron R. Szewczuk¹. Advancements in Polymer Science: ‘Smart’ Drug Delivery Systems for the Treatment of Cancer. 2017 MOJ Poly Sci 1(3): 00016. 3 Head, Department of Chemistry and Chemical Engineering, Sawyer Mod 5, Rm 5512, Royal Military College of Canada, PO Box 17000, Station Forces Kingston, ON K7K 7B4, Canada. ²contributing first authors. DOI: 10.15406/mojps.2017.01.00016
Manpreet Sambi1,2 & Fiona Haxho1,2, Bessi Qorri1,2, William Harless3*, Myron R. Szewczuk1*. Pancreatic Adenocarcinoma: Current Therapies and Challenges. 2017 Adv Res Gastroentero Hepatol 4(4): ARGH.MS.ID.555643 (2017) 001, submitted April 15, 2017, accepted for publication April 18, 2017 as it stands in current form. 2contributing first authors. 3ENCYT Technologies, Inc. Membertou, NS, Canada. https://juniperpublishers.com/argh/pdf/ARGH.MS.ID.555643.pdf
Stephanie N. Allison Logan1,2, Amanda J. Brissenden1, Myron R. Szewczuk3, and Ronald J. Neufeld1. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly (lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival. Drug Design, Development and Therapy 2017 Volume 2017:11 Pages 2239—2250, submitted March 24, 2017, published 31 July 2017. 1Chemical Engineering, Queen's University. 2Polymer Science Group, Department of Chemical and Biomolecular Engineering, University of Melbourne, Parkville, Victoria 3010, Australia. DOI https://doi.org/10.2147/DDDT.S137934
Fiona Haxho^1#, Manpreet Sambi^1#, Bessi Qorri^1#, William Harless² and Myron R. Szewczuk¹. Current clinical challenges and emerging multi-modal approaches for the treatment of pancreatic cancer. Clin Oncol. 2017;2: 1296. (Impact factor 1.92, indexed PubMed). ¹Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada; ²ENCYT Technologies, Inc. Membertou, NS, Canada. ^#These authors have contributed equally. http://clinicsinoncology.com/
Sabah Haq, Fiona Haxho, Vanessa Samuel, Roman Akasov, Maria Leko, Sergey V. Burov, Elena Markvicheva and Myron R. Szewczuk.Sialylation facilitates self-assembly of 3D multicellular prostaspheres using cyclo-RGDfK(TPP) peptide. OncoTargets and Therapy 2017:10 2427–2447, accepted March 08, 2017, as it stands in current form. http://www.ncbi.nlm.nih.gov/pubmed/28496342
Manpreet Sambi, Sabah Haq, Vanessa Samuel, Bessi Qorri, Fiona Haxho, Kelli Hill, William Harless and Myron R. Szewczuk. Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. Breast Cancer - Targets and Therapy 2017:9 1–9. Received 23rd December 2016, Accepted 15th February 2017 as it stands in current form. DOI https://doi.org/10.2147/BCTT.S130838
Manpreet Sambi and Myron R. Szewczuk. KRAS mutations: efficacy and sensitivity of early predictive screening of cancer progression require other gene mutations in addition to KRAS. Translational Cancer Research 2017;6(Suppl 1) S15-S17. Received 8th December 2016, Accepted 11th December 2016 as it stands in current form. DOI: http://dx.doi.org/10.21037/tcr.2017.01.05

Intellectual Property

Patents

European Patent Application No. 21771275.1
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTION AND RESPIRATORY COMPROMISE
ENCYT TECHNOLOGIES, INC.; Myron R SZEWCZUK

National Phase Entry in Canada of International Application No. PCT/CA2021/050362
Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTION AND RESPIRATORY COMPROMISE
Applicant: ENCYT TECHNOLOGIES, INC.; Myron R. SZEWCZUK
Reference #: 55983477-9CA
Norton Rose Fulbright Canada LLP / S.E.N.C.R.L., s.r.l.
222 Bay Street, Suite 3000, P.O. Box 53, Toronto ON M5K 1E7 Canada

National Phase Entry in United States of International Application No. PCT/CA2021/050362
Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTION AND RESPIRATORY COMPROMISE
Applicant: ENCYT TECHNOLOGIES, INC.; Myron R. SZEWCZUK
Reference #: 55983477-9US
Norton Rose Fulbright Canada LLP / S.E.N.C.R.L., s.r.l.
222 Bay Street, Suite 3000, P.O. Box 53, Toronto ON M5K 1E7 Canada

CANCER TREATMENT AND METASTASIS INHIBITION USING AN ANTI-CANCER STEM CELL AGENT IN COMBINATION WITH A NEU1 SIALIDASE INHIBITOR OR A CYTOKINE INHIBITOR AFTER PRIMARY CANCER TREATMENT. The United States No. 16/312,828 Confirmation No. 2441
Date Issued: October 01, 2022
Inventors: Myron R. Szewczuk and William W. Harless
Value - commercialization Impact - clinical trials

Method for evaluating protection to bee venom. The United States. 5124249. 2089/11/28.
Patent Status: Granted/Issued

Canadian Patent No. 2,858,246 - Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer Your Reference:. . 2,858,246.
Patent Status: Granted/Issued
Year Issued: 2020
Inventors: Szewczuk

COMPOSITIONS AND METHODS FOR THE TREATMENT OF THREATENED RESPIRATORY FAILURE CAUSED BY CORONAVIRUS INFECTION AND DISEASE. The United States. 55983477-9USPR. 2020/03/18.
Patent Status: Pending
Year Issued: 2020
Inventors: Myron R. Szewczuk and William Warren Harless>

French Patent No. 2773340 - Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer. 2773340.
Patent Status: Granted/Issued
>Year Issued: 2019
Inventors: Szewczuk

Switzerland Patent No. 2773340 - Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer. Switzerland. 2773340.
Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Szewczuk

Chinese Patent No. ZL201180076213.7 - Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer. ZL201180076213.7.
>Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Szewczuk

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer (Spanish Patent No. 2773340). Spain. 2773340.
Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Szewczuk

Swedish Patent No. 2773340 - Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer. 2773340.
Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Szewczuk

German Patent No. 602011064575.7 - Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer. 602011064575.7.
Patent Status: Granted/Issued
>Year Issued: 2019
Inventors: Szewczuk

UK Patent No. 2773340 - Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer. United Kingdom. 2773340.
Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Szewczuk

Italian Patent No. 502020000014650 - Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer. Italy. 502020000014650.
Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Szewczuk

Compositions and methods for cancer treatment (Canadian Patent). Canada. PCT/CA2017/050768. 2017/06/22.
Patent Status: Allowed
Year Issued: 2019
Inventors: William Harless and Myron R. Szewczuk
Compositions and methods for cancer treatments Contribution value - commercialization Impact - clinical trial

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer (Canadian Patent). Canada. Canadian Patent number 2,858,246. 2014/07/07.
Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Myron R. Szewczuk
Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer Value - commercialization Impact - clinical >trials

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer (European Patent). Germany. European Patent Application No. 11874886.2. 2014/07/07.
Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Myron R. Szewczuk
Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer Value - commercialization Impact - clinical trials

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer (Chinese Patent). China. Chinese Patent No. 201180076213.7. 2014/07/07.
Patent Status: Pending
Year Issued: 2019
Inventors: Myron R. Szewczuk
Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer Value - commercialization Impact - clinical trials

Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer (United States Patent). United States. United States Patent US 2015/0064282 A1. 2014/07/07.
Patent Status: Granted/Issued
Year Issued: 2019
Inventors: Myron R. Szewczuk
Use of Neu1 Sialidase Inhibitors in the Treatment of Cancer Value - commercialization Impact - clinical trials

Method to improve the effectiveness of anticancer therapies by exposing to an inflammatory stimulus prior to treatment (Canadian Patent). Canada. PCT/CA2017/ 050765. 2017/06/22. Patent Status: Allowed
Year Issued: 2017
Inventors: William Harless and Myron R, Szewczuk
Exposing cancer cells to an inflammatory stimulus before treatment Impact - Clinical trials

Use of oseltamivir phosphate and analogs thereof to treat cancer (International PCT Patent). Canada. International PCT/CA2011/050690. 2012/11/04.
Patent Status: Granted/Issued
Year Issued: 2013
Inventors: Paul Josefowitz and Myron Szewczuk
Use of oseltamivir phosphate and analogs thereof for the treatment of cancer

Team